InsiderTrades

Form 4 for BIIB Biogen

Accepted 2024-02-05 00:00:00 ET · period of report 2024-02-01 · accession 0001127602-24-003440 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-02-05 2024-02-01 BIIB Singhal Priya Head of Development M - OptEx $0.00 +1,828 5,292 +53% $0
D 2024-02-05 2024-02-02 BIIB Singhal Priya Head of Development S - Sale+OE $245.93 -634 4,097 -13% -$155.9K
D 2024-02-05 2024-02-01 BIIB Singhal Priya Head of Development F - Tax $247.83 -561 4,731 -11% -$139.0K
D 2024-02-05 2024-02-01 BIIB Singhal Priya Head of Development M - OptEx $0.00 -1,828 3,657 -33% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-02-01 M A 1,828 $0.00 5,292.09 D — —
2 Common Common Stock 2024-02-02 S D 634 $245.93 4,097.09 D — —
3 Common Common Stock 2024-02-01 F D 561 $247.83 4,731.09 D — —
4 Derivative Restricted Stock Unit 2024-02-01 M D 1,828 $0.00 3,657 D $0.00 · — to 2026-02-01 1,828 Common Stock (F1) This award was granted to the reporting person on February 1, 2023 and will vest in three equal installments on each anniversary of the grant date.